Sexual Dysfunction Related to Psychotropic Drugs: A Critical Review Part II: Antipsychotics

A. La Torre 1, A. Conca 2, D. Duffy 1, G. Giupponi 2, M. Pompili 1, M. Grözinger 1

1 U.O. di Psichiatria, Ospedale di Rovereto, Rovereto (Tn), Italy
2 Servizio Psichiatrico del Comprensorio Sanitario di Bolzano, Bolzano, Italy
3 Department of Psychiatry, Sant'Andrea Hospital, “La Sapienza” University of Rome, Rome, Italy
4 Klinik für Psychiatrie, Psychotherapie und Psychosomatik des Universitätsklinikums, Aachen, Germany

Abstract

Sexual dysfunction is a potential side effect of antipsychotic drugs: this article presents a critical review of the current literature. Although many studies have been published on the subject, only some used a validated sexual function rating scale and most lacked either a baseline or placebo control or both. In addition, many of the studies on sexual dysfunction associated with antipsychotic medication are limited by other methodological flaws. However, there is consistent evidence to suggest that a large number of antipsychotic drugs adversely affect one or more of the 3 phases of sexual response (desire, arousal and orgasm). Among the antipsychotics, the so called “prolactin-raising” are probably most associated with sexual dysfunction, even if further studies to confirm this are needed: the reviewed literature shows no consistent evidence that any one antipsychotic drug has a significantly superior side effect profile over another and current information on this topic is often based on methodologically weak research. Clinicians must be aware of drug-induced sexual dysfunction, since its presence can have important consequences for clinical management and compliance.

Introduction and Methods

This study was conducted using the paper and electronic resources of the library of the Azienda Provinciale per i Servizi Sanitari (APSS) in Trento, Italy (http://atoz.ebsco.com/Title/2793). The library has access to a wide range of databases including (DYNAMED, MEDLINE Full Text, CINAHL Plus Full Text), The Cochrane Library, Micromedex healthcare series, BMJ Clinical Evidence. The full list of available journals can be viewed at http://atoz.ebsco.com/Title/2793, or at the APSS web site (http://www.apss.tn.it).

In completing this review, a literature search was conducted using the key words “antipsychotic drugs”, “psychotropic drugs”, “sexual dysfunction”, “sexual side effects”, “treatment-emergent sexual dysfunction”. All resulting listed articles were reviewed.

Sexual Dysfunction Induced by Antipsychotics

Epidemiology

Increasing evidence indicates that sexual dysfunction is common among patients prescribed antipsychotic medication: until a few years ago, this problem was largely neglected by research teams [1–4], and sexual side effects induced by antipsychotic medication received only modest attention [5,6]. The reasons for this are several. Firstly, previous research tended to focus mainly on the effects of the underlying disease on the patient’s sexuality, describing sexual disorders and behaviour associated with psychotic symptoms [7–9]. Secondly, patients, especially those suffering from schizophrenia, rarely spontaneously report sexual dysfunction [10]. In addition, similar to patients taking antidepressants, patients with psychosis are more likely to report sexual side effects if directly questioned about them. Studies that relied only on spontaneous reporting of side effects, report low rates of sexual dysfunction, while studies using structured interviews or questionnaires show higher rates of sexual dysfunction [3,11,12]. Despite this finding, in clinical practice psychiatrists often continue to underestimate the importance of formally enquiring about sexual dysfunction among their patients. It should be noted that some researchers [13–18] included iatrogenic endocrine disorders (amenorrhea, galactorrhea and gynae-
Table 1 Classification of sexual dysfunctions in DSM IV TR.

<table>
<thead>
<tr>
<th>Sexual Desire Disorders</th>
<th>Sexual Arousal Disorders</th>
<th>Orgasmic Disorders</th>
<th>Sexual Pain Disorders</th>
<th>Sexual Dysfunction due to a General Medical Condition</th>
<th>Substance Induced Sexual Dysfunction</th>
<th>Sexual Dysfunction not Otherwise Specified</th>
</tr>
</thead>
</table>

Mechanism of action of antipsychotics on sexual function

Antipsychotic drugs exert numerous different actions on cell receptors in the central nervous system (CNS). They can also cause endocrine disturbances by increasing prolactin. Different hypotheses have been suggested for the mechanism of action of antipsychotics on sexual function (Table 2), including dopamine receptor antagonism, increased prolactin (secondary to dopaminergic antagonist action), blockage of alpha-adrenergic receptor (antidopaminergic action), blockage of acetylcholine receptors (anticholinergic action), serotonin antagonist action, and histamine antagonist action.

<table>
<thead>
<tr>
<th>Drug effect</th>
<th>Physiological effect</th>
<th>Sexual function effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>dopamine receptor antagonism</td>
<td>inhibition of motivation and reward</td>
<td>decreased desire</td>
</tr>
<tr>
<td>dopamine D2 receptor antagonism (tuberoinfundibular pathway)</td>
<td>hyperprolactinemia</td>
<td>decreased desire, impaired arousal, impaired orgasm</td>
</tr>
<tr>
<td>histamine receptor antagonism</td>
<td>sedation</td>
<td>impaired arousal</td>
</tr>
<tr>
<td>cholinergic receptor antagonism</td>
<td>reduced peripheral vasodilation</td>
<td>erectile dysfunction</td>
</tr>
<tr>
<td>α-adrenergic α-receptor antagonism</td>
<td>reduced peripheral vasodilation</td>
<td>priapism, decreased erection/lubrification, abnormal ejaculation</td>
</tr>
</tbody>
</table>

The variation in prevalence rates is related to several factors, but is mainly due to the different methodological approaches adopted by different studies: studies that relied only on spontaneous reporting of side effects, report low rates of sexual dysfunction, while studies using structured interviews or questionnaires show higher rates of sexual dysfunction. It should be noted that some researchers included iatrogenic endocrine disorders (amenorrhea, galactorrhea and gynecomastia) in their definition of sexual dysfunction which is not in keeping with international classifications (ICD-10, DSM-IV-TR), and which may therefore have affected the data on prevalence rates. Also, the definition of sexual dysfunction used by some investigators only included “decreased libido” and “impotence/sexual dysfunction”, without considering other areas of sexual dysfunction.
tic properties are associated with priapism [50]. Although antipsychotics can induce relatively isolated effects on the neurotransmitters involved in the response cycle, the mechanism of action leading to sexual dysfunction is more complex. Sexual side effects often occur in combination, and pharmacological effects on one component may have an indirect effect on another area of sexual functioning. Furthermore, the etiology of sexual dysfunction may in many cases be multifactorial [2].

Hyperprolactinemia is caused by blockage of dopamine D2 receptors in the hypothalamic infundibular system [51–55]. Dopamine (DA) has an antagonistic effect on the production of prolactin (one of the hormones most implicated in sexual response). Hence, the use of antipsychotics can lead to a decrease in dopamine and a consequent rise in prolactin, which can inhibit sexual function.

Sexual dysfunction is most prevalent in patients with hyperprolactinemia; a correlation between antipsychotic-induced hyperprolactinemia and sexual dysfunction rates has also been documented [2, 3, 5, 20, 26, 30, 44, 51, 56–61]. This correlation, however, is neither confirmed [15, 62–67] nor clear [68, 69] in other studies. There have also been reported cases of sexual dysfunction with normal prolactin levels [70, 71]: in these cases, the sexual dysfunction was probably associated with other physical (e.g., diabetes) or psychological (e.g., quality of partner relationship) factors.

It is unclear whether sexual dysfunction correlates to a direct effect and/or an indirect effect of hyperprolactinemia. Increased prolactin levels, inhibit the hypothalamic release of GnRH (gonadotropin releasing hormone), a hormone that releases gonadotropins, follicle stimulating hormone (FSH) and luteinizing hormone (FSH) from the anterior pituitary gland. The end result of an increase in prolactin, may therefore consist of a reduction in levels of gonadal hormones (e.g., decreased levels of estrogen in women and testosterone in men) [9, 44, 72]. During long-term treatment with typical antipsychotics, it is reported that women have significantly more elevated prolactin levels than men [73]. Increased prolactin levels are also more common among women [3, 74]. Smith et al. [75], for example, found that after 2 years on antipsychotics medication, 75% of women and 34% of men had high levels of prolactin.

An increase in prolactin is very common among psychotic patients treated with a first generation antipsychotic, but also with risperidone and amisulpride [3, 23, 59, 76, 77]. Based on these observations, some authors make the distinction between antipsychotics that elevate prolactin levels (so-called "prolactin-raising") and those that have minimal and/or transient effects on prolactin levels ("prolactin-sparing") [59, 72, 78, 79]. It is worth highlighting that hyperprolactinemia is not always accompanied by clinical symptoms (such as amenorrhea, or gynecomastia) [73].

In addition to direct pharmacological effects (such as, for example, the antagonistic action on dopamine receptors) and endocrine dysfunction, other pharmacological side effects including sedation (mainly related to antihistaminergic action), extrapyramidal effects and weight gain, can indirectly reduce sexual desire [85].

It is difficult to evaluate the effects of antipsychotic drugs on sexual function in patients with schizophrenia because they are often superimposed on sexual impairment caused by the disease itself [25]. In a comparison group study comparing schizophrenic patients on antipsychotic medication with schizophrenic patients taking no medication and healthy individuals with no schizophrenia, there was a high rate of sexual dysfunction in both patient groups [86].

### Antipsychotics and sexual dysfunction

Antipsychotic-induced side effects on sexual function are usually inhibitory in nature and may affect all phases of the sexual response cycle. These effects include decreased sexual desire ("libido"), difficulties with erection, achieving orgasm and sexual satisfaction, as well as ejaculation disorders (delayed or inhibited ejaculation, retrograde ejaculation, spontaneous ejaculation in the absence of sexual stimulation, decreased ejaculatory volume) [20, 72, 85, 87, 88].

Data from the early literature generally showed that (i) all antipsychotics are associated with decreased sexual desire [89], (ii) Most antipsychotics are associated with erectile dysfunction. Those most frequently cited in the literature include: chlorpromazine, pimozide, thioridazine, thiotixene and sulpiride [90]. (iii) Thoridazine was probably one of the first antipsychotic drugs identified as having the ability to cause delayed ejaculation [90]. (iv) There are many case reports on antipsychotic-induced anorgasmia: among these, the most frequently cited antipsychotic is thioridazine [89], followed by trifluoperazine [91]. (v) Priapism is a possible side effect of all antipsychotic drugs [92], particularly for phenothiazines (chlorpromazine, fluphenazine and thioridazine), although more recently isolated cases have been reported with aripiprazole [93], clozapine, flupenthixol [89], olanzapine, quetiapine [94, 95], risperidone [25] and ziprasidone [95–97].

Table 3 Prolactin and antipsychotics (from Baggaley [30], Maguire [54]; Montejo [59]; Montgomery et al. [84]).

<table>
<thead>
<tr>
<th>Antipsychotic</th>
<th>Prolactin-raising</th>
<th>Prolactin-sparing</th>
</tr>
</thead>
<tbody>
<tr>
<td>amisulpride</td>
<td>☑</td>
<td>☑</td>
</tr>
<tr>
<td>aripiprazole</td>
<td>☑</td>
<td>☑</td>
</tr>
<tr>
<td>asenapine</td>
<td>?</td>
<td>?</td>
</tr>
<tr>
<td>clozapine</td>
<td>☑</td>
<td>☑</td>
</tr>
<tr>
<td>haloperidol</td>
<td>☑</td>
<td>☑</td>
</tr>
<tr>
<td>iloperidone</td>
<td>?</td>
<td>?</td>
</tr>
<tr>
<td>lurasidone</td>
<td>?</td>
<td>?</td>
</tr>
<tr>
<td>olanzapine</td>
<td>☑</td>
<td>☑</td>
</tr>
<tr>
<td>paliperidone</td>
<td>☑</td>
<td>☑</td>
</tr>
<tr>
<td>quetiapine</td>
<td>☑</td>
<td>☑</td>
</tr>
<tr>
<td>risperidone</td>
<td>☑</td>
<td>☑</td>
</tr>
<tr>
<td>ziprasidone</td>
<td>☑</td>
<td>☑</td>
</tr>
</tbody>
</table>

? = limited data available, although some evidence to indicate minimal effect on prolactin levels for asenapine [80, 81], iloperidone [82], and lurasidone [83].

To date, most of the studies conducted have been observational comparison studies of various typical and atypical antipsychotic drugs. The number of randomized controlled trials that specifically focus on antipsychotic induced sexual dysfunction is small [4].

The interpretation of data relating to the assessment of sexual functioning is complex because of the different assessment tools and study methods adopted in the various studies, making it difficult to compare findings. The conclusions reached by the various researchers as summarized below, are not definitive and they are difficult to interpret and need to be confirmed by further studies [98–100].
In this review we have provided a summary of the main conclusions reached by studies in the current literature, as well as summarizing the most salient information on individual drugs. Serretti et al. [11], in a recent meta-analysis (which included data on studies investigating sexual dysfunction related to treatment with antipsychotics) showed that quetiapine, ziprasidone, perphenazine and aripiprazole were associated with relatively low rates of sexual dysfunction (16–27%), whereas olanzapine, risperidone, haloperidol, clozapine and thioridazine were associated with higher rates of sexual dysfunction (40–60%). In the randomized double-blind study by Kelly et al. [101] (with a sample size of only 27 patients) the side effects of fluphenazine, quetiapine and risperidone were compared. Patients experienced high rates of sexual dysfunction with each of these drugs (78% with fluphenazine, 50% with quetiapine, and 42% with risperidone). Symptom improvement, mainly with regards to arousal/erection, was observed during the trial only in those patients treated with quetiapine. The authors concluded that quetiapine has a better side effect profile than the other two drugs. In a randomized open label comparison study by Knegtering et al. [102] (comparing the atypical antipsychotics, risperidone and olanzapine), 46 patients initially taking a typical antipsychotic, were switched to risperidone or olanzapine. Olanzapine was found to cause less sexual dysfunction. In a study on 199 patients using combined data from an open and combined study, Knegtering et al. [3] concluded that typical antipsychotics and risperidone (considered to be prolactin-raising) are associated with higher rates of sexual dysfunction (decreased libido, problems with orgasm) compared to prolactin-sparing antipsychotics (clozapine, olanzapine, quetiapine and sertindole).

In an observational study by Bobes et al. [103] conducted in Spain on 636 patients, lower rates of sexual dysfunction were found with quetiapine (18%) compared to olanzapine (35%), haloperidol (38%) and risperidone (43%). In another observational study by Uçok et al. [104] conducted on 827 stable patients, it was reported that over 50% of patients experienced sexual dysfunction. Patients receiving poly-pharmacy experienced more severe side effects than those taking a single second-generation antipsychotic.

In the study by Nakonezny et al. [105] (conducted on a sample of 22 men) a switch from risperidone to quetiapine was not associated with any improvement in sexual function, assessed using a 5 item questionnaire. Byerly et al. [106] using adjusted average ASEX (Arizona Sexual Experience Scale) rating scale scores, reported less severe sexual dysfunction with quetiapine compared to olanzapine and risperidone: however, these differences, were not clinically significant. Nagaraj et al. [107] also found no statistically significant differences in sexual dysfunction induced by risperidone, olanzapine and quetiapine: in this study, sexual function was measured using the SFQ (Sexual Functioning Questionnaire), which revealed a reduction in overall sexual functioning in 96% of cases for risperidone, 90% for olanzapine and 88% for quetiapine. Another study by Byerly et al. [108] did not show any statistically significant difference in sexual functioning (as assessed by ASEX) after switching from risperidone to quetiapine.

Dossenbach et al. [31] conducted an observational study on 3838 patients. Sexual problems were common among all patients taking antipsychotic drugs, although there were no statistically significant differences in prevalence: haloperidol (71%), risperidone (68%), quetiapine (60%), olanzapine (56%). In an observational study by Stroese et al. [109], conducted over only 12 weeks, comparing risperidone, olanzapine and clozapine, a worsening of sexual performance was reported in men only for each of these 3 drugs. A study by Bitter et al. [110] showed a mild improvement in sexual function with olanzapine (compared to risperidone), which however was limited to libido.

In a study by Mahmoud et al. [111], it was reported that sexual functioning (as measured by the SR-DISF: Derogatis Interview for Sexual Function) of 42 schizophrenics improved after a switch from typical to atypical antipsychotics (amisulpride, olanzapine, quetiapine and risperidone) in spite of the fact that two of the atypical antipsychotic drugs prescribed (amisulpride and risperidone) are noted for their capacity to induce sexual dysfunction.

Montejo et al. [112] conducted an observational cross-sectional study on a sample of 243 patients with a diagnosis of psychotic disorder and found (using the PRSexDQ-SalSex) that 46% of patients experienced sexual dysfunction, among whom those treated with risperidone and typical antipsychotics had a significantly increased risk of sexual dysfunction. In the Table 4 we have summarized the effect of individual antipsychotic drugs on sexual dysfunction (SD).

### Treatment of sexual dysfunction induced by antipsychotics

Some recommended treatment approaches for the management of sexual dysfunction induced by antipsychotic drugs include the following: (i) A thorough clinical evaluation, to exclude comorbid conditions (physical and psychiatric) or sexual dysfunction secondary to alcohol or illicit drug use or other prescribed medication. The assessment should include measurement of serum prolactin in patients presenting with side effects suggestive of hyperprolactinemia [2, 74]. (ii) Modification of risk factors (where possible, avoid use of other drugs associated with sexual dysfunction, smoking cessation, abstinence from alcohol and illicit drugs, maintaining normal blood sugar levels in diabetic patients, treatment of hypertension and hypercholesterolemia). (iii) In the early phase of treatment, if possible, consider waiting for a spontaneous improvement in side effects [63]. (iv) Reduction in dose of antipsychotic drug responsible for side effects. (v) Switch to another antipsychotic drug with a more tolerable side effect profile (ideally a “prolactin-sparing” antipsychotic) [59]. (vi) Addition of symptom targeted therapy – using dopaminergic drugs (amantadine, bromocriptine, cabergoline) or drugs with specific effects on sexual functioning (such as phosphodiesterase inhibitors or yohimbine) [1,2,5, 23,72,140,141]. In a study by Inder et al., selegiline was not found to alleviate symptoms of antipsychotic-induced sexual dysfunction [142]. Sildenafil may be a useful option in the treatment of antipsychotic-induced sexual dysfunction in men [141]. In general, the evidence supporting the addition of symptomatic therapies is weak [1,2,143].

### Conclusions

All antipsychotics drugs can cause sexual dysfunction, although it is extremely difficult to accurately determine the true prevalence. This review confirms that antipsychotic-induced sexual
dysfunction is common among patients taking antipsychotic medication. The conclusions reached by the different researchers are not definitive and are difficult to interpret mainly because of the significant differences in methods used for assessing sexual function: further studies are needed on the underlying causes and types of sexual dysfunction, and on the factors linking antipsychotic use and sexual dysfunction, in particular with regard to the specific mechanisms of action including alterations in prolactin levels and binding to dopaminergic, histaminergic, cholinergic, serotoninergic and 

<table>
<thead>
<tr>
<th>Table 4 Sexual dysfunction (SD) and antipsychotics.</th>
</tr>
</thead>
<tbody>
<tr>
<td>amisulpride</td>
</tr>
<tr>
<td>aripiprazole</td>
</tr>
<tr>
<td>clozapine</td>
</tr>
<tr>
<td>haloperidol</td>
</tr>
<tr>
<td>olanzapine</td>
</tr>
<tr>
<td>quetiapine</td>
</tr>
<tr>
<td>risperidone and paliperidol.</td>
</tr>
<tr>
<td>ziprasidone</td>
</tr>
</tbody>
</table>

Conflict of Interest

The authors declare no conflicts of interest.

References

16 Haro JM, Salvador-Carulla L. The SOHO (Schizophrenia Outpatient Health Outcome) study. Implications for the treatment of schizophrenia. CNS Drugs 2006; 20: 293–301.
206

Review

20 Compton MT, Miller AJ. Sexual side effects associated with conventional and atypical antipsychotics. Psychopharmacol Bull 2001; 35: 89–108

27 Foster P, Mottard K, Trudel G et al. Study of sexuality-related characteristics in young adults with schizophrenia treated with novel neuroleptics and in a comparison group of young adults. Schizophr Bull 2003; 29: 559–572

29 Apantaku-Olajide T, Gibbons P, Higgins A. Drug-induced sexual dysfunction and mental health patients’ attitude to psychotropic medications. Sex Relation Ther 2011; 26: 145–155
30 Baggaley M. Sexual dysfunction in schizophrenia: focus on recent evidence. Hum Psychopharmacol 2008; 23: 201–209
34 Khwaja MY. Sexual dysfunction in male patients taking antipsychotics. J Ayub Med Coll Abbottabad 2005; 17: 73–75
42 Knechtgter H, Blijd C, Boks MMP. Sexual dysfunction and prolactin levels in patients using classical antipsychotics, risperidone or olanzapine. Schizophr Res 1999; 36: 355–356
43 Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 2007; 21: 91–113
46 Knechtgter H, Bruggeman R. What are the effects of antipsychotics on sexual functioning? Prim Psychiatry 2007; 14: 51–56
51 Bhuvaneswar CG, Balsdessarini RJ, Harsh VL et al. Adverse endocrine and metabolic effects of psychotropic drugs. CNS Drugs 2009; 23: 1003–1021
100 Kelly DL, Conley RR. A randomized double-blind 12-week study of quietaperine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. Psychoneuroendocrinology 2006; 31: 340–346


104 Nakonezny PA, Byerly MJ, Rush AJ. The relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind trial of risperidone vs. quetiapine. J Sex Marital Ther 2007; 33: 203–216

105 Byerly MJ, Nakonezny PA, Betcher BM et al. Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine. Schizophr Res 2006; 86: 244–256


107 Byerly MJ, Nakonezny PA, Rush AJ. Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: A randomized double-blind pilot trial. Psychopharmacol 2008; 195: 115–120


118 Casey DE, Carson WH, Salha AR et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacol 2003; 166: 391–399


128 Kinon BJ, Ahl J, Liu-Seifert H et al. Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. Psychoneuroendocrinology 2006; 31: 577–588